Pulmonary exacerbation treatment by age group
| Age group | |||
|---|---|---|---|
| <18 years N=43 | ≥18 years N=80 | All N=123 | |
| Duration of intravenous antibiotics | |||
| Mean (SD) | 14.0 (5.6) | 18.2 (9.8) | 16.7 (8.8) |
| n (%) | |||
| 0–10 days | 11 (25.6) | 9 (11.3) | 20 (16.3) |
| >10–14 days | 21 (48.8) | 26 (32.5) | 47 (38.2) |
| >14–21 days | 8 (18.6) | 31 (38.8) | 39 (31.7) |
| >21 days | 3 (7.0) | 14 (17.5) | 17 (13.8) |
| Location of treatment | |||
| n (%) | |||
| Exclusively hospital | 28 (65.1) | 35 (43.8) | 63 (51.2) |
| Exclusively home | 0 (0) | 21 (26.3) | 21 (17.1) |
| Both hospital and home | 13 (30.2) | 23 (28.8) | 36 (29.3) |
| Unknown | 2 (4.7) | 1 (1.3) | 3 (2.4) |
| Number of intravenous antibiotics | |||
| n (%) | |||
| 1 | 1 (2.3) | 1 (1.3) | 2 (1.6) |
| 2 | 23 (53.5) | 46 (57.5) | 69 (56.1) |
| 3 | 16 (37.2) | 25 (31.3) | 41 (33.3) |
| 4+ | 3 (7.0) | 8 (10.0) | 11 (8.9) |
| Most common intravenous antibiotics | |||
| n (%) | |||
| Tobramycin | 22 (51.2) | 54 (67.5) | 76 (61.8) |
| Meropenem | 12 (27.9) | 45 (56.3) | 57 (46.3) |
| Ceftazidime | 7 (16.3) | 27 (33.8) | 34 (27.6) |
| Vancomycin | 18 (41.9) | 11 (13.8) | 29 (23.6) |
| Cefepime | 11 (25.6) | 12 (15.0) | 23 (18.7) |
| MRSA* active drug | |||
| n (%) | 28 (65.1) | 36 (45.0) | 64 (53.0) |
| Inhaled antibiotics | |||
| n (%) | 5 (11.6) | 7 (8.8) | 12 (9.8) |
| Oral antibiotics | |||
| n (%) | 5 (11.6) | 22 (27.5) | 27 (22.0) |
| Steroids | |||
| n (%) | 7 (16.3) | 13 (16.3) | 20 (16.3) |
*Received any of doxycycline, linezolid, minocycline, rifampin, tigecycline, trimethoprim/sulfamethoxazole or vancomycin.
MRSA, methicillin-resistant Staphylococcus aureus.